Aromatase inhibitors and breast cancer prevention

作者：Litton Jennifer Keating^*; Arun Banu K; Brown Powel H; Hortobagyi Gabriel N

来源：Expert Opinion on Pharmacotherapy, 2012, 13(3): 325-331.

DOI：10.1517/14656566.2012.651459

• anastrozole
• aromatase inhibitors
• breast cancer
• exemestane
• letrozole
• prevention

Introduction: Endocrine therapy with selective estrogen receptor modulators (SERMs) has been the mainstay of breast cancer prevention trials to date. The aromatase inhibitors, which inhibit the final chemical conversion of androgens to estrogens, have shown increased disease-free survival benefit over tamoxifen in patients with primary hormone receptor-positive breast cancer, as well as reducing the risk of developing contralateral breast cancers. The aromatase inhibitors are being actively evaluated as prevention agents for women with a history of ductal carcinoma in situ as well as for women who are considered to be at high risk for developing primary invasive breast cancer. %26lt;br%26gt;Areas covered: This review evaluates the available prevention data, as evidenced by the decrease in contralateral breast cancers, when aromatase inhibitors are used in the adjuvant setting, as well as the emerging data of the aromatase inhibitors specifically tested in the prevention setting for women at high risk. %26lt;br%26gt;Expert opinion: Exemestane is a viable option for breast cancer prevention. We continue to await further follow-up on exemestane as well as other aromatase inhibitors in the prevention setting for women at high risk of developing breast cancer or with a history of ductal carcinoma in situ.

• 出版日期2012-2